An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer

Individualization of cancer management requires prognostic markers and therapy-predictive markers. Prognostic markers assess risk of disease progression independent of therapy, whereas therapy-predictive markers identify patients whose disease is sensitive or resistant to treatment. We show that an experimentally derived IFN-related DNA damage resistance signature (IRDS) is associated with resistance to chemotherapy and/or radiation across different cancer cell lines. The IRDS genes STAT1, ISG15, and IFIT1 all mediate experimental resistance. Clinical analyses reveal that IRDS(+) and IRDS(−) states exist among common human cancers. In breast cancer, a seven–gene-pair classifier predicts for efficacy of adjuvant chemotherapy and for local-regional control after radiation. By providing information on treatment sensitivity or resistance, the IRDS improves outcome prediction when combined with standard markers, risk groups, or other genomic classifiers.

[1]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[2]  Bernard Roizman,et al.  Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. , 2007, Cancer research.

[3]  M. Kattan,et al.  How to judge a tumor marker , 2005, Nature Clinical Practice Oncology.

[4]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Michael W Kattan,et al.  Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.

[6]  Richard Simon,et al.  Roadmap for developing and validating therapeutically relevant genomic classifiers. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Daniel Q. Naiman,et al.  Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data , 2005, Bioinform..

[8]  C. Redmond,et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. , 1995, New England Journal of Medicine.

[9]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[10]  Karen A Gelmon,et al.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Daniel Q. Naiman,et al.  Simple decision rules for classifying human cancers from gene expression profiles , 2005, Bioinform..

[12]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[13]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[14]  James B. Mitchell,et al.  Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation. , 2007, Cancer research.

[15]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[16]  Richard M. Simon,et al.  Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data , 2002, Bioinform..

[17]  A. Nobel,et al.  Concordance among Gene-Expression – Based Predictors for Breast Cancer , 2011 .

[18]  W. Merrick,et al.  Viral Stress-inducible Protein p56 Inhibits Translation by Blocking the Interaction of eIF3 with the Ternary Complex eIF2·GTP·Met-tRNAi* , 2003, Journal of Biological Chemistry.

[19]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  E Shelley Hwang,et al.  Identification of a robust gene signature that predicts breast cancer outcome in independent data sets , 2007, BMC Cancer.

[21]  Hemant Ishwaran,et al.  Random Survival Forests , 2008, Wiley StatsRef: Statistics Reference Online.

[22]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[23]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[24]  Steven Gygi,et al.  Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  W. Gerald,et al.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy , 2005, Cancer.

[27]  Bernard Roizman,et al.  STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[29]  C. Perou,et al.  Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. , 2004, Cancer cell.

[30]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[32]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[33]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[34]  S. Horvath,et al.  Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.

[35]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[36]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[37]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[38]  Steven Eschrich,et al.  Prediction of radiation sensitivity using a gene expression classifier. , 2005, Cancer research.

[39]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.